A Study of Azacitidine in Participants With International Prognostic Scoring System (IPSS) Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS), or Chronic Myelomonocytic Leukemia (CMML), or Acute Myeloid Leukemia (AML)
The purpose of this study is to assess the safety and effectiveness in the real-world setting among participants who are treated with Azacitidine in accordance with the China Product Label.
Myelodysplastic Syndromes|Leukemia, Myelomonocytic, Chronic|Leukemia, Myeloid, Acute
Incidence of Adverse Events (AEs), Up to 12 Months|Incidence of Serious Adverse Events (SAEs), Up to 12 Months|Incidence of Adverse Drug Reactions (ADRs), Up to 12 Months
Best Overall response rate (ORR) defined as the proportion of participants who achieved best response of superior to stable disease, Up to 12 Months
This study will have participants both enrolled retrospectively and prospectively for azacitidine (AZA) treatment.